FDA Classification Setback Bodes Well For Wound Care Cos.
By Steven Gonzalez, Peter Dickos and Adrienne Lenz · November 3, 2026, 2:15 PM EST
In MiMedx Group Inc. v. U.S. Food and Drug Administration,[1] the U.S. District Court for the Northern District of Georgia on Sept. 21 handed the regenerative medicine industry a significant win, vacating...
To view the full article, register now.